For the quarter ending 2026-01-31, PMCB had $4,759,518 increase in cash & cash equivalents over the period.
| Cash Flow | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 |
|---|---|---|---|---|
| Other non-cash income | - | - | - | 0 |
| Net income (loss) | 746,860 | -7,417,975 | -8,360,096 | 30,656,050 |
| Gain on related party investment tnf | - | - | 0 | 21,395,734 |
| Gain on related party investment qcls | 0 | 2,089,000 | - | - |
| Adjustment from accrued liabilities to warrant liabilities | - | -938,000 | 469,000 | - |
| Asset impaired | - | - | - | 0 |
| Issuance costs series c preferred stock and warrants | 0 | 1,234,553 | - | - |
| Loss on long term asset | - | - | - | 0 |
| Loss on issuance of series c preferred stock | 0 | 215,000 | - | - |
| Non-cash warrant liability | - | - | - | 469,000 |
| Gain on re-fair value of warrants | 0 | 0 | 106,000 | - |
| Non-cash interest income | 300,000 | - | - | 300,000 |
| Change in fair value of investment tnf | - | - | -2,839,000 | 5,063,950 |
| Stock issued for compensation - rsus | 771,516 | 60,492 | 60,492 | 478,637 |
| Change in fair value of warrants - tnf | - | - | -4,832,000 | -2,367,684 |
| Stock-based compensation - options | 181,476 | - | - | - |
| Unrealized loss on marketable equity securities | -128,939 | -60,663 | -104,463 | 66,316 |
| Change in fair value of warrant liabilities | 1,895,865 | -10,474,000 | 243,000 | 10,446,000 |
| Change in fair value of derivative liability | 557,000 | 302,000 | 0 | 2,184,000 |
| Change in fair value of convertible note receivable - femasys | 0 | 392,000 | 912,000 | 941,000 |
| Change in fair value of warrant asset femasys | -214,000 | -726,000 | -1,215,000 | -2,091,000 |
| Change in fair value of investment qcls | 1,725,000 | -5,210,000 | - | - |
| Change in fair value of warrants - qcls | -1,200,000 | 1,218,000 | - | - |
| Decrease in prepaid expenses and other current assets | -344,483 | 264,967 | 14,421 | -36,041 |
| Increase in accounts payable | 178,743 | 469,711 | 66,005 | 9,835 |
| Decrease in accrued expenses | -544,000 | -75,000 | -1,006,424 | 1,310,457 |
| Net cash and cash equivalents used in operating activities | -786,848 | -979,523 | -1,993,981 | -2,978,296 |
| Investment in preferred stock and warrants | - | 3,000,000 | 0 | 7,000,000 |
| Proceeds from investment - note receivable | 5,000,000 | - | - | - |
| Investment convertible note receivable and warrants | - | - | - | 0 |
| Investment in preferred stock and warrants in qcls | 3,000,000 | - | - | - |
| Proceeds from issuance of preferred stock, net of transaction costs | - | - | - | 0 |
| Net cash and cash equivalents provided by (used in) investing activities | 5,000,000 | -3,000,000 | 0 | -7,000,000 |
| Repurchase of common stock, net | 401,625 | 0 | 0 | 2,542,276 |
| Redemption of preferred stock | 0 | 0 | 0 | 22,486,875 |
| Net proceeds from issuance of series c convertible preferred stock | 0 | 6,268,866 | - | - |
| Net proceeds from exercises of warrants | 1,046,760 | - | - | 0 |
| Accrued series c convertible preferred stock and dividends | - | 61,250 | - | - |
| Payment of series c convertible preferred stock dividends | 162,606 | - | - | - |
| Net cash and cash equivalents provided by (used in) financing activities | 543,779 | 6,207,616 | 0 | -25,029,151 |
| Effect of currency rate exchange on cash and cash equivalents | 2,587 | -381 | 123 | -358 |
| Net increase (decrease) in cash and cash equivalents | 4,759,518 | 2,227,712 | -1,993,858 | -35,007,805 |
| Cash and cash equivalents at beginning of the period | 15,406,017 | 15,172,163 | - | - |
| Cash and cash equivalents at end of the period | 20,165,535 | 15,406,017 | - | - |
PharmaCyte Biotech, Inc. (PMCB)
PharmaCyte Biotech, Inc. (PMCB)